statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of...

Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors

Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire...

Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Spyre Therapeutics Announces Grants of Inducement Awards Spyre Therapeutics Announces Grants of Inducement Awards PR Newswire WALTHAM, Mass., May 3, 2024 WALTHAM, Mass., May 3, 2024 /PRNewswire...

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Announces Grants of Inducement Awards Spyre Therapeutics Announces Grants of Inducement Awards PR Newswire WALTHAM, Mass., April 1, 2024 WALTHAM, Mass., April 1, 2024 /PRNewswire...

Spyre Therapeutics (NASDAQ:SYRE - Free Report) had its price objective increased by Stifel Nicolaus from $36.00 to $54.00 in a report released on Tuesday, Benzinga reports. They currently have a buy...

Spyre Therapeutics (NASDAQ:SYRE) Price Target Increased to $54.00 by Analysts at Stifel Nicolaus

Spyre Therapeutics, Inc. (NASDAQ:SYRE  Get Free Report) has been given an average rating of Buy by the seven analysts that are currently covering the firm, Marketbeat Ratings...

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of "Buy" by Analysts

Over the last three days, A.I.dvisor has detected that SYRE's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

Spyre Therapeutics (SYRE, $37) Aroon Indicator entered an Uptrend on March 27, 2024.

Spyre Therapeutics (SYRE, $37.61) Aroon Indicator entered an Uptrend on March 26, 2024.

Spyre Therapeutics (SYRE, $38.48) Aroon Indicator entered an Uptrend on March 25, 2024.

This indicator may be signaling that SYRE's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Spyre Therapeutics (SYRE, $38.48) entered Downtrend as Momentum indicator drops below 0 level on Mar 25, 2024

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Watchers	2,083
52-Wk Low	$2.66
52-Wk High	$47.97

Volume	308,277.00
52-Wk High	$47.97
52-Wk Low	$2.66

SYRE Aeglea BioTherapeutics Inc

About

Feed

News

Sentiment

Fundamentals